POTASSIUM TARTRATE HEMIHYDRATE

US Approved OTC

First marketed in 1921

Details

Stereochemistry	ABSOLUTE
Molecular Formula	2C4H4O6.4K.H2O
Molecular Weight	470.5504
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of POTASSIUM TARTRATE HEMIHYDRATE

Structure Search

SMILES

O.[K+].[K+].[K+].[K+].O[C@H]([C@@H](O)C([O-])=O)C([O-])=O.O[C@H]([C@@H](O)C([O-])=O)C([O-])=O

InChI

InChIKey=FRFCDHONTUJIBX-JEPRPBJASA-J

InChI=1S/2C4H6O6.4K.H2O/c2*5-1(3(7)8)2(6)4(9)10;;;;;/h2*1-2,5-6H,(H,7,8)(H,9,10);;;;;1H2/q;;4*+1;/p-4/t2*1-,2-;;;;;/m11...../s1

HIDE SMILES / InChI

Molecular Formula	H2O
Molecular Weight	18.0153
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	K
Molecular Weight	39.0983
Charge	1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C4H4O6
Molecular Weight	148.071
Charge	-2
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/29764543 | https://www.mayoclinic.org/drugs-supplements/potassium-supplement-oral-route-parenteral-route/description/drg-20070753 | https://www.ncbi.nlm.nih.gov/pubmed/28419159

Potassium is needed to maintain good health. When potassium level falls below 3.5 mmol/L, Hypokalemia is diagnosed. In case of extremely low level of potassium (lower than 2.5 mmol/L) the following symptoms are appeared: malaise and fatigue. This low level of potassium can lead to severe muscle weakness and paralysis; respiratory failure; intermittent muscle spasms. It is known, foods that are good sources of potassium and low in sodium may reduce the risk of high blood pressure and stroke. Potassium supplementation is also recommended as an adjuvant antihypertensive agent for patients with essential hypertension.

Approval Year

Conditions

Condition	Modality	Targets	Highest Phase	Product
essential hypertension 23 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28419159	Palliative		Phase III 663	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
		96279836
Mineral and water nutrition.	1991 Jul	1893277
Age sensitivity to organophosphate-induced delayed polyneuropathy. Biochemical and toxicological studies in developing chicks.	1991 May 15	2018554
Diet, genetics and hypertension.	1997 Aug	9263178
Inhibition of HIV-1 infection by zinc group metal compounds.	1999 Sep	10517314
Crystal structures of Tritrichomonasfoetus inosine monophosphate dehydrogenase in complex with substrate, cofactor and analogs: a structural basis for the random-in ordered-out kinetic mechanism.	2003 Feb 14	12559919

Patents

Sample Use Guides

In Vivo Use Guide

Potassium is administered in various dosage forms (gluconate, citrate, chloride, bicarbonate). Exact dose should be determined by a doctor. Most people will not take more than 100 mEq a day.

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Thu Jul 06 00:04:37 UTC 2023` Edited by `admin` on `Thu Jul 06 00:04:37 UTC 2023`
Record UNII	GM5EY0N07D
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

POTASSIUM TARTRATE HEMIHYDRATE

Common Name

English

KALI TARTARICUM

Common Name

English

TARTARIC ACID, DIPOTASSIUM SALT, HEMIHYDRATE

Common Name

English

BUTANEDIOIC ACID, 2,3-DIHYDROXY- (2R,3R)-, POTASSIUM SALT, HYDRATE (2:4:1)

Common Name

English

KALI TARTARICUM [HPUS]

Common Name

English

DIPOTASSIUM TARTRATE HEMIHYDRATE

Common Name

English

BUTANEDIOIC ACID, 2,3-DIHYDROXY- (2R,3R)-, DIPOTASSIUM SALT, HYDRATE (2:1)

Common Name

English

Code System Code Type Description

CAS

6100-19-2